CC
BBOT

Casdin Capital’s BridgeBio Oncology BBOT Stock Holding History

Casdin Capital’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.53M Hold
282,312
– – 0.19% 35
2025
Q4 		$3.53M Hold
282,312
– – 0.22% 31
2025
Q3 		$3.27M Buy
+282,312
New +$2.94M 0.27% 24

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Casdin Capital's BBOT Position: Q1 2026 in Review

Casdin Capital held its BridgeBio Oncology (BBOT) position steady in Q1 2026 at 282,312 shares worth $2.53M. The position accounts for 0.19% of the portfolio, ranked #35.

Casdin Capital first reported a position in BBOT in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.53M in Q4 2025. 67 funds tracked by Wall St. Rank hold BBOT as of Q1 2026.

  • Casdin Capital held 282,312 shares of BridgeBio Oncology worth $2.53M as of Q1 2026.
  • Casdin Capital left its BridgeBio Oncology share count unchanged in Q1 2026.
  • BridgeBio Oncology made up 0.19% of Casdin Capital's portfolio in Q1 2026, its #35 holding.
  • Casdin Capital first reported a position in BridgeBio Oncology in Q3 2025 and has held it in 3 quarters since.
  • Casdin Capital's BridgeBio Oncology position peaked at $3.53M in Q4 2025.
  • 67 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q1 2026.

Based on Casdin Capital's 13F filing for Q1 2026, filed 15 May 2026.